This study compares two oral medicines used to treat active vitiligo, a condition where white patches on the skin keep spreading. One medicine is Tofacitinib, and the other is Betamethasone given in mini-pulse doses.

COMPARATIVE STUDY OF THERAPEUTIC EFFECTIVENESS OF ORAL TOFACITINIB VERSUS BETAMETHASONE ORAL-MINI PULSE THERAPY IN TREATMENT OF UNSTABLE VITILIGO PATIENT IN OPD - NIL

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2026/03/105470

Enrollment

Registered

2026-03-06

Start date

Unknown

Completion date

Unknown

Last updated

2026-03-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: L80- Vitiligo

Interventions

Intervention1: ORAL TOFACITINIB: ORAL TOFACITINIB 5MG TWICE DAILY FOR 12 WEEKS IN PATIENTS WITH UNSTABLE VITILIGO Control Intervention1: ORAL BETAMETHASONE MINI PULSE: ORAL BETAMETHASONE MINI PULSE TH

Eligibility

Inclusion criteria

Inclusion criteria: Patients aged 18 50 years Clinical diagnosis of unstable vitiligo Previously untreated patient Consenting Patient

Exclusion criteria

Exclusion criteria: Patients with stable vitiligo History of severe infections or immunosuppression Pregnant or lactating women Known hypersensitivity to Tofacitinib or corticosteroids Patients with uncontrolled diabetes, hypertension, or other serious comorbidities Patients currently on systemic immunomodulatory therapy for other diseases

Design outcomes

Primary

Measure	Time frame
Reduction in VASI Score from baseline to 12 weeks Timepoint: Baseline 4 Weeks 8 Weeks 12 Weeks	—

Secondary

Measure	Time frame
nilTimepoint: nil	—

Countries

India

Contacts

Public ContactSAMYAK JAIN

MGM MEDICAL COLLEGE, INDORE

priticadebnath@gmail.com7974890077

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Apr 4, 2026